Hillhurst Bio reports first subject dosed in Phase 2a trial of HBI-002 for Parkinson's disease

Lonza and Antharis Therapeutics enter target-specific licence agreement

Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes

Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment

Sensei Biotherapeutics changes name to Faeth Therapeutics

Bayer receives FDA approval for AMBELVIST MRI contrast agent

Johnson & Johnson commits over USD1bn to expand Vision manufacturing in Jacksonville

Genmab reports strong epcoritamab results in elderly newly diagnosed DLBCL patients

AstraZeneca secures US approval for Truqap combination in PTEN‑deficient prostate cancer

Acousia Therapeutics reports positive top-line efficacy results for ACOU085 in cisplatin-induced ototoxicity

Transcend Therapeutics acquired by Otsuka Pharmaceutical

Lilly reports initial clinical data for type II JAK2 inhibitor in patients with previously treated myelofibrosis

Menarini reports Phase 3 data for selinexor plus ruxolitinib in myelofibrosis

Simcere Pharmaceutical and Stanford Medicine agree research collaboration in idiopathic pulmonary fibrosis

ABL Diagnostics secures clinical research contract worth up to EUR2.7m through 2031